WuXi-MedImmune Biologic Drug Begins China IND Review

WuXi PharmaTech, China's largest CRO/CMO, announced that the CFDA accepted an IND filing to begin clinical trials of WuXi MedImmune's novel anti-IL6 monoclonal antibody, a potential treatment for rheumatoid arthritis. In 2012, WuXi and MedImmune, the biologics subsidiary of AstraZeneca, formed a JV for China development of the drug, which had already started a Phase I dose-escalation trial in the US and Europe. The JV filed the IND with the Jiangsu provincial FDA as a Class 1 therapeutic biologic. More details.... Stock Symbols: (NYSE: WX) (NYSE: AZN) Share this with colleagues: // //